• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Catalent Acquires Delphi Genetics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    test company saurabh

    Reed-Lane

    Almac Group

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Adare Pharma Solutions

    Alcami

    test company saurabh

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Bio-Outsourcing On the Rise

    Fewer companies go 100% in-house

    Related CONTENT
    • Catalent Acquires Delphi Genetics
    • Avid Bioservices Begins Phase 2 of Myford Mfg. Expansion
    • Intravacc Unveils New Pilot Vaccine Production Facility
    • RedHill and Cosmo Strengthen Manufacturing Agreements
    • Lilly, Rigel Enter Exclusive CNS Development Collaboration
    Eric S. Langer09.07.11

    For the first time since 2008, the number of biotherapeutic developers manufacturing 100% in-house has dropped in each production system surveyed. According to data released in BioPlan Associates' 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1 for the first time since we began measuring outsourcing, more than half of respondents using mammalian cell culture or microbial fermentation systems report that they are now outsourcing at least some of their manufacturing.1


    Our annual study provides indicators of global outsourcing activities, and points to the increasing use of CMOs to control costs and manage internal staff and resources. Among many areas of coverage, this year’s survey asked respondents the percentage of production currently outsourced by manufacturing method — mammalian, microbial, yeast, plant, and insect — and compared the data to previous years. The results, which include responses from 352 global biomanufacturers, show that biologics developers recognize that, as their production capacity constraints shift, bio-CMOs can provide the necessary technical expertise and flex capacity to reduce risks associated with building internal capacity. 
     


    Biopharma CMOs are expanding their manufacturing competence through the use of novel technologies, single-use/disposable bioreactors and other differentiated bioprocessing services. Expansions are resulting in increased adaptability, lower costs, faster turnaround and higher yields. For clients, this means that more CMOs are likely to meet their needs (more competition leads to more choice). In addition, the costs for using CMOs for product manufacturing are holding steady, even as service offerings improve. This year’s study shows CMO pricing to remain virtually flat, with only bulk formulating increasing around an average of 2%. Most of the other 10 CMO areas tested will remain below a 1% price increase this year. 


    Outsourcing Results


    This year, among respondents producing in mammalian cell culture, 45% indicated they performed all their production “in-house” (down from last year’s 57%). In addition, 17.6% of respondents outsourced less than 10% of their production, and 16.2% outsourced from 10% to 25%. Over the past few years, the percentage of biotherapeutic developers who are doing all of their mammalian cell production “in-house” shifted down slightly from 55.6% in 2006 to 57% in 2010, and to 45% today. 


    For microbial fermentation, 43.8% of this year’s respondents indicated they performed all their production “in-house,” vs. 64.2% last year, while 8.3% of respondents outsourced 90-100% of their production. The percentage of biotherapeutic developers who were doing all their microbial fermentation “in-house” has increased slightly over the past five years (between 58.1% in 2005 vs. 64.2% last year, and 43.8% this year). 
     


    Interestingly, in comparison with other manufacturing platforms, insect cell culture was reported to be done 65% in-house, (followed by 59.1% doing yeast culture in-house). With few insect and plant cell production platforms being used for commercial manufacture, this indicates that these systems are primarily being used for in-house manufacture of preclinical and perhaps some early clinical supplies. The overall trend toward using more outsourcing is paralleled by the fact that more “platform processes” are becoming available, a fact that supports outsourcing.


    Key Findings 


    • Mammalian cell systems: 45% (vs. 57% last year, and 53% the previous year) of respondents indicated that they outsourced no production.

    • Microbial: 43.8% (vs. 64.2% last year, and 60% in 2009) outsourced no production.

    • Yeast: 59.1% (vs. 60.7% last year, and 69% in 2009) outsourced no production.

    • Plant cells: 58% outsourced no production (compared with 75% last year).

    • Insect cells: 65% outsourced no production. 


    Looking Ahead: Five-Year Projections For Outsourcing Activities


    Respondents also estimated the overall percentage of their production that they expected to outsource by 2015. The trend our study shows towards greater outsourcing in all manufacturing platforms is supported by data concerning future projections. Indeed, this year, 63.5% of respondents projected that at least some production in mammalian cell culture will be outsourced within five years, compared with 63.1% last year (and 53.5% the previous year).
    The fact that mammalian systems manufacturers have not significantly changed their five-year projection this year suggests a relatively stable production environment. For microbial fermentation, 59.6% of respondents this year indicated that at least some of their fermentation will be outsourced within five years. In comparison, 52.7% last year and 43.9% in 2009 indicated they would outsource at least some microbial production. Additionally, companies expecting to outsource at least some insect cell production expanded significantly to 44.4% this year, up from only 16.7% in 2010. Data regarding outsourcing of yeast, plant and insect cell production show greater year-on-year variability due to the relatively smaller percentage of facilities operating in these systems. 


    Trends in Outsourcing Activities


    Outsourcing today continues to be dominated by relatively lower value-added services, such as fill/finish and product testing. To dig deeper into outsourcing trends, and to determine where the greatest changes are likely to occur, we examined 23 current outsourcing activities and asked respondents which areas they will be outsourcing more often over the next 24 months.

    We discovered that the primary outsourced activity today is product characterization testing, with over 70% of biopharmaceutical companies outsourcing at least some of this activity. Validation services (69.3%) and plant maintenance services (67.1%) follow closely. At the other end of the scale, there appears to be relatively low outsourcing activity for design of experiments, downstream and upstream process development, and QbD initiatives. 


    One activity that showed a significant increase in outsourcing from last year was API biologics manufacturing, which jumped to 44.3% of respondents who are now outsourcing at least some of this activity (compared to 29.3% in 2010). This increase is reflected in the growth of companies such as Albany Molecular Research, Inc. (AMRI), whose president and chief executive officer, Thomas E. D'Ambra, attributed its strong second quarter results to “continued strength in development and large scale API manufacturing operations as both biotech and pharmaceutical companies maintain focus on their late-stage portfolios.”2


    API outsourcing for biologics has been around for decades, with Lonza in the UK and Boehringer Ingelheim leading in mammalian and microbial systems, respectively. Today, we are seeing an expansion of CMOs and biosimilar manufacturers (see www.top1000bio.com) globally due to the emergence of facilities in India, China, Korea, Malaysia and elsewhere. These facilities are emerging to support both domestic production, and to gain a foothold in the developing opportunities for biologics production. In addition, despite the current stable capacity worldwide for biological manufacturing, drug innovator companies continue to offer their excess or idle capacity as CMO operations. 


    Outsourcing Growth Trends


    We evaluated outsourcing trends by asking respondents where they believed they would be outsourcing significantly more projects over the next 24 months. Of the 24 activities tested, three stood out as areas where substantial changes will occur during the next two years. We found that 23% of biomanufacturers will be outsourcing significantly more ‘Fill/finish operations’ compared with their current levels. Although this figure is slightly down from 2010 (25%), there appears to be a trend towards more outsourcing of this activity in the future, as more and more “high-end” fill/finish operations are used, such as prefilled syringes, cartridge systems and multi-use adjustable syringes. 
     


    Following fill/finish operations is ‘validation services,’ noted by 22.1% as being a big gainer over the next 24 months. Validation services result from a lack of internal staff with the ‘brain-power’ and ‘hands-on’ capacity to provide the corresponding know-how when it comes to late stage process / methods validation in a company that wants to rapidly move from early-stage clinic into late stage and commercial. Highly specialized providers of validation services have been active for many years and their businesses continue to prosper. 


    Following ‘validation services’ as a future outsourcing activity was ‘downstream production operations,’ which was noted by 22.0% of respondents this year (compared to 14.3% in 2010). According to Dr. Wolfgang Noe, senior consultant at BioProcess Technology Consultants, this may be due to the fact that “more companies tend to outsource the ‘standard, platform’ processes, while focusing internally around the more challenging molecules.”1


    While the world economy continues to take a battering, biopharmaceuticals and related industry segments remain growth areas. Even so, the biopharma industry is becoming rapidly globalized — according to our recently released Top 1000 Global Biopharmaceutical Manufacturing Index™,3 although the U.S. has the largest concentration of global biomanufacturing capacity (not just number of facilities), at 37.5%, China (8.5%), India (8.0%), and Japan & other Asian countries (9.2%) are growing rapidly. 


    Given this increasingly competitive global environment, the biopharma industry continues to focus on productivity, efficiency, getting more out of existing internal resources, and maximizing performance from provider relationships. Outsourcing plays a role in this equation as companies recognize the strategic necessity of using internal resources more efficiently, while outsourcing activities outside their core competencies. This outsourcing of processes, while enabling a focus on a company’s skill base, also yields economic benefits. Even so, as CMOs offer expertise, tools and capacity that biopharma companies don’t have in-house — or that they elect to outsource as part of their strategic planning — it will increasingly become less about direct cost savings, and more about doing things better and more competitively.


    Although outsourcing can improve overall efficiency and reduce costs, the management of relationships continues to be challenging, and necessitates flexibility to meet clients’ shifting needs. The rise of outsourcing has resulted in many companies establishing centralized contracting groups to handle the complex and time-consuming business of selecting and managing partners. Our study indicates that this growth is also resulting in ongoing and, in many cases, unresolved problems associated with managing relationships, partners and projects. These problems are likely to continue to expand along with current outsourcing trends. As the use of outsourcing partners becomes more embedded into company strategy, effective management, including the establishment and maintenance of strong working relationships will become more critical. Addressing these managerial, communications, and partnering problems may become a bottleneck that determines just how quickly and successfully the outsourcing industry grows. 

     

    References

    1 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates, April 2011, 490 pages.

    2 AMRI Announces Second Quarter Results. 8 August, 2011. http://www.marketwatch.com/story/amri-announces-second-quarter-2011-results-2011-08-08?reflink=MW_news_stmp

    3 BioPlan’s Top 1000 Global Biopharmaceutical Facilities Index™, www.top1000bio.com, accessed August 25, 2011

     

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a Rockville, MD-based biotechnology and life sciences marketing research and publishing firm established in 1989. He can be reached at elanger@bioplanassociates.com or 301-921-5979.

     

    Survey Methodology: The 2011 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production in the series of annual evaluations by BioPlan Associates, Inc. yields a composite view and trend analysis from 352 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 31 countries. The methodology also encompassed an additional 186 direct suppliers of materials, services and equipment to this industry. This year's survey covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world's major markets in the U.S. and Europe.

    Related Searches
    • contracting
    • biopharma companies
    • contract manufacturing organizations
    • Manufacturing
    Suggested For You
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    Avid Bioservices Begins Phase 2 of Myford Mfg. Expansion Avid Bioservices Begins Phase 2 of Myford Mfg. Expansion
    Intravacc Unveils New Pilot Vaccine Production Facility Intravacc Unveils New Pilot Vaccine Production Facility
    RedHill and Cosmo Strengthen Manufacturing Agreements RedHill and Cosmo Strengthen Manufacturing Agreements
    Lilly, Rigel Enter Exclusive CNS Development Collaboration Lilly, Rigel Enter Exclusive CNS Development Collaboration
    Pfizer, BioNTech To Supply 200M More Vax Doses to EU Pfizer, BioNTech To Supply 200M More Vax Doses to EU
    Novavax, SK Bioscience Expand Vax Pact Novavax, SK Bioscience Expand Vax Pact
    Charles River Acquires CDMO Cognate BioServices Charles River Acquires CDMO Cognate BioServices
    Kaneka Eurogentec Expands Capabilities Kaneka Eurogentec Expands Capabilities
    FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    RotaChrom Technologies Partners with Cyclolab RotaChrom Technologies Partners with Cyclolab
    Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    CureVac, UK Partner on Vaccines Against SARS-CoV-2 Variants CureVac, UK Partner on Vaccines Against SARS-CoV-2 Variants
    Sepha Launches Small Batch Contract Packaging Service Sepha Launches Small Batch Contract Packaging Service

    Related Bio News & Views

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development

      CMOs Demanding More Innovations

      Chromatography and single-use equipment top list
      Eric Langer , BioPlan Associates 11.13.13

    • Biologics, Proteins, Vaccines | Capsules | Clinical Trial Materials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Parenterals | Process Development | QA/QC | Validation

      How Far Do You Go?

      ...
      Victor A Vinci, Ph.D., Cook Pharmica 06.05.13

    • Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Scale-up/Technology Transfer
      Future Bio-Capacity Constraints

      Future Bio-Capacity Constraints

      Top 10 factors from a new survey
      Eric S. Langer, BioPlan Associates, Inc. 09.06.12


    • Analytical Services | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Capsules | Cleaning Validation | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Process Development | Process Validation | Regulatory Affairs | Scale-up/Technology Transfer | Toxicology | Validation

      The FDA Says You Are Responsible

      . . . But do you know who you are?
      E. Morrey Atkinson, Ph.D., Cook Pharmica 05.04.12

    • Bio News | Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development
      Industry Adopting More Complex Devices

      Industry Adopting More Complex Devices

      CMOs are spending twice as much as bio-innovators on single-use devices
      Eric S. Langer, BioPlan Associates, Inc. 03.07.12

    • Biologics, Proteins, Vaccines | Capsules | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | R&D | Scale-up/Technology Transfer

      Whose Platform Is It Anyway?

      Both Sides of the Table
      E. Morrey Atkinson, Ph.D. 01.23.12


    • Biologics, Proteins, Vaccines | Extractables and Leachables | Facilities | GMPs/GCPs | Methods Development | Process Development | Process Validation | QA/QC | Validation

      Why Not Do an Engineering Lot?

      Both Sides of the Table – A discussion of CMO/client perspectives
      E. Morrey Atkinson. Ph.D. 10.11.11

    Trending
    • Century Therapeutics Significantly Expands Capabilities
    • Catalent Acquires Delphi Genetics
    • Sanofi And Translate Bio Expand Vaccine Collaboration
    • RotaChrom Technologies Partners With Cyclolab
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    Breaking News
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    • Catalent Acquires Delphi Genetics
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Previon, Spectrum Solutions Partner to Deliver At-Home COVID-19 Test
    NTT Research, Japanese Entity to Collaborate on Cardiovascular Disease Interventions
    Global Peripheral Intravenous Catheter Market to Reach $7.5 Billion by 2027
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    ACG Launches ACG Laboratories
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Afro Sheen Launches New Brand Initiatives
    Neopac Introduces Lightweight Plastic Tube
    Estée Lauder Companies Increases Investment in Deciem Beauty Group Inc.
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Ontex Reports Lower Revenues
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OrthoGrid Releases New Hip Replacement Software
    Nexus Spine Announces Availability of Spine Surgery Implants
    FDA OKs Brainlab's Loop-X Mobile Imaging Robot, Cirq Robotic Alignment Module
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login